Exciting news from our portfolio company @CybinInc! FDA clearance for CYB004's Phase 2a GAD study marks a significant step in advancing mental health solutions. Kudos to @insidepharma and the Cybin team for their dedication. #Innovation#MentalHealth#Cybin
#BREAKING: The FDA has cleared Cybin's investigational new drug application for CYB004 — our proprietary deuterated DMT molecule — allowing us to proceed with a Phase 2a GAD study of CYB004 in Q1 2024.
"We have gathered important insights on dosing and preliminary efficacy
Innovating Capital presents a Portfolio Spotlight on @CybinInc. 🧠 Revolutionizing mental healthcare with proprietary molecules like #CYB003 & #CYB004, reshaping treatments for Major Depressive Disorder & Generalized Anxiety Disorder. #Cybin#InnovatingCapital$CYBN
Deep dive on investing and infrastructure with @panthonylg from @PastelNetwork & @InnovatingCap
We discuss:
- Decentralized AI in Web3
- Investing in Infrastructure over DApps
- Strategies for Building Successful Crypto Companies